• Relay Therapeutics posted a Q2 net loss of $83.7 million, unchanged at $0.41 per share, while revenue fell 41.6% to $0.4 million.
• R&D spending rose 19.7% to $76.5 million, driving a wider operating loss of $90.8 million.
• Cash, cash equivalents and investments climbed to $910.9 million at June 30 from $642.1 million at March 31, supported by a May follow-on offering.
• Selected zovegalisib with atirmociclib as the go-forward triplet for first-line breast cancer; a Phase 3 study is expected to start in early 2027.
• Continued the Phase 3 ReDiscover-2 trial in second-line breast cancer; ReInspire vascular anomalies trial showed a 60% volumetric response at 12 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805493) on August 06, 2026, and is solely responsible for the information contained therein.